Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) TNFSF9 Antibodies:
anti-Mouse (Murine) TNFSF9 Antibodies:
anti-Human TNFSF9 Antibodies:
Go to our pre-filtered search.
Human Monoclonal TNFSF9 Primary Antibody for FACS - ABIN2688965
Chu, DeBenedette, Stiernholm, Barber, Watts: Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells. in Journal of immunology (Baltimore, Md. : 1950) 1997
Show all 4 Pubmed References
Mouse (Murine) Monoclonal TNFSF9 Primary Antibody for BR, FACS - ABIN2688839
Akiba, Miyahira, Atsuta, Takeda, Nohara, Futagawa, Matsuda, Aoki, Yagita, Okumura: Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. in The Journal of experimental medicine 2000
Show all 4 Pubmed References
Human Monoclonal TNFSF9 Primary Antibody for ELISA, FACS - ABIN610414
Hutton, Christofori, Chi, Edman, Guest, Hanahan, Kelly: Molecular cloning of mouse pancreatic islet R-cadherin: differential expression in endocrine and exocrine tissue. in Molecular endocrinology (Baltimore, Md.) 1994
Show all 3 Pubmed References
Human Monoclonal TNFSF9 Primary Antibody for ICC, FACS - ABIN1169256
Gullo, Koh, Pang, Ho, Tan, Schwarz: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. in PLoS ONE 2010
Human Polyclonal TNFSF9 Primary Antibody for CyTOF, FACS - ABIN4900479
Ek, Björck, Högerkorp, Nordenskjöld, Porwit-MacDonald, Borrebaeck: Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. in International journal of cancer 2006
the role of CD137 (show TNFRSF9 Antibodies)-CRDI (cysteine rich domain I) in the binding of CD137 (show TNFRSF9 Antibodies)-CD137L was further investigated.
Data indicate that anti-CD137 (show TNFRSF9 Antibodies) agonists can function as inhibitors of CD137L signaling, resulting in the creation of tumor microenvironments unfavorable for tumor immune evasion.
Constitutive interaction between 4-1BB (show TNFRSF9 Antibodies) and 4-1BBL on murine LPS (show TLR4 Antibodies)-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS (show PTK6 Antibodies)-1 but not 19H3 antibody.
4-1BBL can restrain effector T cell development, creating a more favorable regulatory T cell to effector cell balance under tolerogenic conditions, and this may be particularly active in mucosal barrier tissues
These results demonstrate that 4-1BBL-engineered DCs can improve CIKs (show TRAF3IP2 Antibodies) cytotoxicity against prostate cancer cells.
these observations suggest that inhibition of the TLR/4 (show TLR4 Antibodies)-1BBL complex formation may be highly efficient in protecting against continued inflammation
4-1BB (show TNFRSF9 Antibodies) mediates the inflammatory responses in obese skeletal muscle by interacting with its ligand 4-1BBL on macrophages.
CD137 (show TNFRSF9 Antibodies)-CD137L interactions mediated via regulation of CyPA (show PPIA Antibodies) contribute to the progression of atherosclerosis.
Data indicate that CD137L deficient mice displayed a variety of immunological dysfunctions.
monocytes interact with iNKT cells to increase expression of 4-1BBL and 4-1BB (show TNFRSF9 Antibodies), and in conjunction with this pathway, maintain their numbers at baseline.
4-1BB (show TNFRSF9 Antibodies) and 4-1BBL qualify as markers for prediction of patients' course and represent a valuable screening target for patients with acute myeloid leukemia (show BCL11A Antibodies) at initial diagnosis.
the results from this study show that the costimulatory 4-1BB ligand fortifies an antigen-rich melanoma cell line with enhanced antigen-specific stimulation of CD8 (show CD8A Antibodies) T cells
blocking of both OX-40L (show TNFSF4 Antibodies) and 4-1BBL reversed radiation-enhanced T-cell killing of human tumor targets as well as T-cell survival and activation.
CD137L is overexpressed in non-small cell lung cancer specimens and positive expression of CD137L was associated with better overall survival.
In vitro immunotherapy is described for anti-prostate cancer effects of cytotoxic T lymphocytes induction by recombinant adenovirus mediated PSMA/4 (show PSMA4 Antibodies)-1BBL dendritic cells.
vaccination with recombinant attenuated Salmonella harboring the CEACAM6 and 4-1BBL gene efficiently increased the number of CD3 (show CD3 Antibodies)+CD8 (show CD8A Antibodies)+ TIL (show TLR1 Antibodies) and NK cells, decreased the number of FOXP3 (show FOXP3 Antibodies) cells and inhibited the development of DMH (show DST Antibodies)-induced colorectal cancer
Elevated plasma levels and monocyte-associated expression of CD137 (show TNFRSF9 Antibodies) ligand in patients with acute atherothrombotic stroke
Hence, the targeted combination of IL-15 (show IL15 Antibodies) and 4-BBL (show TP53 Antibodies) in the form of a trifunctional antibody-fusion protein is a promising new approach for cancer immunotherapy.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.
, tumor necrosis factor (ligand) superfamily, member 9
, 4-1BB ligand
, tumor necrosis factor ligand superfamily member 9
, homolog of mouse 4-1BB-L
, receptor 4-1BB ligand